Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study

S E Nielsen, F Persson, E Frandsen, T Sugaya, G Hess, D Zdunek, K J Shjoedt, H-H Parving, Peter Rossing

66 Citationer (Scopus)

Abstrakt

Adding aldosterone receptor blockade to standard renoprotective treatment may provide additional renoprotection in patients with overt nephropathy. We expected an impact of spironolactone in early diabetic nephropathy, and for this hypothesis we studied the effect on markers of glomerular and tubular damage in patients with Type 1 diabetes and persistent microalbuminuria.
OriginalsprogEngelsk
TidsskriftDiabetic Medicine
Vol/bind29
Udgave nummer8
Sider (fra-til)e184-90
ISSN0742-3071
DOI
StatusUdgivet - 2012
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study'. Sammen danner de et unikt fingeraftryk.

Citationsformater